Physician profile
Samer E Bibawi
NPI 1528038759
$4,270.23
in general payments reported to CMS, 2019-2025
47 companies · $297 in 2025
The $297 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $377 · 2021: $233 · 2022: $580 · 2023: $758 · 2024: $908 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.07 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,775.90 | 2019-2025 | Gallant, Aveir, Ensite |
| Integra Lifesciences Corporation | $183.44 | 2022-2023 | Codman Certas, Codman Hakim, Cusa Clarity |
| Janssen Biotech, INC. | $177.95 | 2019-2025 | Rybrevant |
| Novocure INC. | $159.75 | 2019-2023 | Optune |
| Davol INC. | $135.61 | 2019 | |
| Sirtex Medical INC | $129.18 | 2019 | |
| Incyte Corporation | $109.25 | 2019-2024 | Jakafi |
| Gilead Sciences, INC. | $108.14 | 2023-2025 | Trodelvy |
| Pfizer INC. | $104.27 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $104.06 | 2019-2023 | Keytruda |
| Tempus Ai, INC | $93.67 | 2024 | |
| Allergan, INC. | $86.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $84.10 | 2019-2025 | Imfinzi, Lynparza |
| Medtronic USA, INC. | $82.05 | 2020 | |
| Novartis Pharmaceuticals Corporation | $68.15 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Bibawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.